All In Biotech

Drug Trial Radar · NCT05471167

Non-specific Effects of BCG in Under-five Children

Last checked: Nov 19, 2026Latest source record: Jul 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80,000

Planned (sponsor's estimate)

Start

Jan 1, 2022

Primary completion

Dec 31, 2022

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Universidade Nova de LisboaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fundação para a Ciência e a Tecnologia
First posted
Jul 22, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 0 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Studies have demonstrated that the reduction in mortality and morbidity due to vaccination extends beyond the targeted infections. This seems to result from the non specific effects of vaccines. BCG, a live attenuated vaccine against TB disease, administered to new borns, is one of the vaccines known to have non specific effects. In Portugal, between 1965 and June 2016, BCG was administered to all new borns. In July 2016, a clinical guideline established that only children under 6 years of age from high-risk groups should be vaccinated. In 2021, the first cohort of children not vaccinated for BCG reached 5 years of age and evidence is needed on the impact of this strategy. Aim: to investigate the incidence of specific and non-specific effects of BCG by comparing the incidence of TB disease and infection, mild and severe morbidity, and mortality in the first 5 years of life of children born between 2010 and 2021 according to their BCG status. Methods: historical birth cohort study of children born between 1st July 2010 and 30th June 2021. The investigators will create a single database that links data from the birth registry, the vaccination registry, the information systems of death certificates, epidemiological surveillance and TB surveillance, Diagnosis Related Groups and of primary health care of children born in the study period to reconstruct chronological sequences of morbidity and mortality events from birth until completion of 5 years of life or 30th June 2021. Only children born in Portugal, live-births and births coded as normal new-born will be included. New borns with low-birth weight (\<2kg), premature (\<37 weeks) and known or suspected HIV infections will not be included in the study. The follow-up period will be until completion of 5 years of age or 30th June 2022. Data will be analysed to compare the incidence of all-cause mortality (including TB), TB disease and severe and mild morbidity among BCG vaccinated and non-vaccinated children born during the reference period in a total of 11 birth cohorts and will comprise computation of person-time incidence rates for primary outcomes and the probability of surviving (Kaplan Meier method) first and fifth year of life or of not having a hospitalization, emergency department visit or a mild morbidity episode during the follow-up period according to exposure. To explore the effects of several variables on the survival outcomes we will use proportional hazards regression analysis.

Conditions

  • Immunity, Heterologous

Interventions

  • BCGBiological

    Exposure is defined as having received the BCG vaccine during the first year of life.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All cause mortalityTime frame: First 5 years of life or until 30 June 2022
  2. Mortality due to TBTime frame: First 5 years of life or until 30 June 2022
  3. Mild morbidityTime frame: First 5 years of life or until 30 June 2022
  4. Severe morbidityTime frame: First 5 years of life or until 30 June 2022
  5. TBTime frame: First 5 years of life or until 30 June 2022

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instituto de Higiene e Medicina Tropical

    Lisbon, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.